國家衛生研究院 NHRI:Item 3990099045/14504
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 855258      在线人数 : 1041
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/14504


    题名: Toward collaboration among cancer trials groups in Asia: TCOG perspective
    作者: Chen, LT
    贡献者: National Institute of Cancer Research
    摘要: It has been well recognized that investigator-initiated academic clinical trials is an important component in developing practice-changing cancer treatment, for instances, FOLFIRINOX in metastatic and resectable pancreatic cancer and FLOT in locally advanced gastric cancer. Because of the difference in prevalent cancer types, pharmacogenomics, tumor biology and/or associated genetic alterations, and new drug approval/reimbursement, clinical practice pattern and subsequent patient outcomes between Eastern and Western populations, the role for such academic clinical intervention trials, including real-world data (RWD) collection registration trials, to investigate the safety and efficacy of repurposing or new agents for new indications evaluation is even more relevant in Asia. Facing the rapid advances in modern biotechnology and biomarker-enriched molecular targeted/immunotherapy, multi-national intergroup study is an attractive model to collect sufficient patients or data in a reasonable period of time for non-industry sponsored trials. Taiwan Cooperative Oncology Group (TCOG) is a government funding supported organization with extensive domestic, multicenter trial experience. However, international collaborative academic trials are much more challenging. From our previous experience, hurdles existed, such as, ethical and privacy protection issue of real world data sharing, funding and medication availability issues for intervention trials, translational tissue acquisition, storage and usage and NGS issue for biomarker-driven trials, etc. The real-world cases will be presented in the meeting!
    日期: 2022-07
    關聯: Annals of Oncology. 2022 Jul;33(Suppl. 6):S449.
    Link to: http://dx.doi.org/10.1016/j.annonc.2022.05.491
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000834940400107
    显示于类别:[陳立宗] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000834940400107.pdf109KbAdobe PDF121检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈